IRIS
TONELLI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.151
Totale 5.151
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.151
Totale 5.151
Salva come PNG Salva come JPEG
Città #
Genova 3.813
Rapallo 684
Genoa 643
Bordighera 10
Vado Ligure 1
Totale 5.151
Salva come PNG Salva come JPEG
Nome #
Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents 185
Clofazimine analogs with antileishmanial and antiplasmodial activity 169
Antiviral activity of benzimidazole derivatives. II Antiviral activity of 2-phenylbenzimidazole derivatives. 157
Quinolizidinyl-benzimidazoles as platelet-antiaggregating agents 143
Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists 137
Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives 137
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus 134
Acridine derivatives as anti-BVDV agents 130
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5 130
Novel celecoxib analogues inhibit glial production of prostaglandinE2, nitric oxide, and oxygen radicals reverting the neuroinflammatoryresponses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide 127
Benzimidazole derivatives endowed with potent antileishmanial activity 124
Inhibition of chloride intracellular channel 1 (CLIC1) as biguanide class-effect to impair human glioblastoma stem cell viability 118
Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells 117
Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR) 113
Pyrazole and imidazo[1,2-b]pyrazole derivatives as new potential anti-tuberculosis agents. 111
Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation 109
Benzimidazole-based derivatives as privileged scaffold developed for the treatment of the RSV infection: a computational study exploring the potency and cytotoxicity profiles 109
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines 108
A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists 106
Multitarget Therapeutic Leads for Alzheimer’s Disease: Quinolizidinyl Derivatives of Bi- and Tricyclic Systems as Dual Inhibitors of Cholinesterases and beta-Amyloid (Abeta) Aggregation 105
Pharmacophore modeling, resistant mutant isolation, docking, and MM-PBSA analysis: Combined experimental/computer-assisted approaches to identify new inhibitors of the bovine viral diarrhea virus (BVDV) 102
Exhaustive CoMFA and CoMSIA analyses around different chemical entities: a ligand-based study exploring the affinity and selectivity profiles of 5-HT1A ligands 102
Antimicrobial and cytotoxic arylazoenamines. Part III: Antiviral activity of selected classes of arylazoenamines 101
Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity 101
Antiviral Activity of Benzimidazole Derivatives. I. Antiviral Activity of 1-Substituted-2-[(Benzotriazol-1/2-yl)methyl]benzimidazoles. 99
New arylsparteine derivatives as positive inotropic drugs 98
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease 95
Synergistic experimental/computational studies on arylazoenamine derivatives that target the bovine viral diarrhea virus RNA-dependent RNA polymerase 94
Exploring the effectiveness of novel benzimidazoles as CB2 ligands: synthesis, biological evaluation, molecular docking studies and ADMET prediction 94
3-(4-Chlorophenyldiazenyl)-1-methyl-1,4,5,6-tetrahydropyridine, 92
9-Aminoacridine-based agents impair the bovine viral diarrhea virus (BVDV) replication targeting the RNA-dependent RNA polymerase (RdRp) 87
Antitubercular and antiprotozoal activities of quinolizidinyl/pyrrolizidinylalkyliminophenazines 83
Fight against H1N1 Influenza A Virus: Recent Insights towards the Development of Druggable Compounds 80
Chapter 1. Non-Nucleoside Benzimidazoles As Antiviral Drugs Against HIV Infections 78
Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives 78
Novel biguanide-based derivatives scouted as TAAR1 agonists: synthesis, biological evaluation, ADME prediction and molecular docking studies 77
Synthesis and antiplasmodial activity of novel chloroquine analogues with bulky basic side chains 75
Celecoxib, a COX-2 inhibitor, blocks microglial activation induced by a neurotoxic conformer of hPrP90-231 69
Quinolizidinyl derivatives of bi- and tricyclic systems as AChE/BchE and beta-amyloid aggregation inhibitors, 66
Exploring the selectivity profile of sigma receptor ligands by molecular docking and pharmacophore analyses. 64
Look Back in Anger. Toxicity vs. Activity for Acridine Derivatives as HCV RNA Dependent RNA-polymerase Inhibitors 62
Molecular mechanisms mediating the neuroprotective effects of quinacrine and minocycline on cell death induced by the prion protein fragment 90-231 (hPrP90-231) 62
Chapter 2. Non-Nucleoside Benzimidazoles As Antiviral Drugs Against HCV and RSV Infections. 59
Multitarget Biological Profiling of New Naphthoquinone and Anthraquinone-Based Derivatives for the Treatment of Alzheimer's Disease 58
Primary anti-proliferative activity evaluation of 1-(quinolizidin-1'-yl)methyl- and 1-([Formula: see text]-tert-amino)alkyl-substituted 2-phenyl-, 2-benzyl- and 2-[(benzotriazol-1/2-yl)methyl]benzimidazoles on human cancer cell lines. 57
Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors 54
Synthesis and biological evaluation of novel (thio)semicarbazone-based benzimidazoles as antiviral agents against human respiratory viruses 49
Journey on naphthoquinone and anthraquinone derivatives: New insights in alzheimer’s disease 48
Targeting species-specific TAAR1 ligands: to date perspective of the rational drug design process 47
New insights into the binding features of f508del cftr potentiators: A molecular docking, pharmacophore mapping and qsar analysis approach 46
Probing In Silico the Benzimidazole Privileged Scaffold for the Development of Drug-like Anti-RSV Agents 42
Host DHFR-directed cycloguanil analogues endowed with promising activity against influenza virus and respiratory syncytial virus 41
New insights into the structure of the Trace Amine-Associated Receptor 2 (TAAR2): homology modeling studies exploring the binding mode of 3-iodothyronamine 39
Quinolizidine-derived lucanthone and amitriptyline analogues endowed with potent antileishmanial activity 37
null 37
null 35
Novel 1-amidino-4-phenylpiperazines as potent agonists at human taar1 receptor: Rational design, synthesis, biological evaluation and molecular docking studies 34
Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present) 33
Evidence of pyrimethamine and cycloguanil analogues as dual inhibitors of trypanosoma brucei pteridine reductase and dihydrofolate reductase 30
New naphtho- and anthraquinone derivatives as Cholinesterase inhibitors for the treatment of Alzheimer's disease 29
State-of-the-art Review on the Antiparasitic Activity of Benzimidazole-based Derivatives: Facing Malaria, Leishmaniasis, and Trypanosomiasis 28
Quinone-based derivatives: a new class of multi-target agents against Alzheimer’s disease 27
Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease 20
Novel Thiazole-Based SIRT2 Inhibitors Discovered via Molecular Modelling Studies and Enzymatic Assays 19
Magnolol and Luteolin Inhibition of α-Glucosidase Activity: Kinetics and Type of Interaction Detected by In Vitro and In Silico Studies 19
Antitarget, Anti-SARS-CoV‑2 Leads, Drugs, and the Drug Discovery−Genetics Alliance Perspective 14
The breakthrough of TAAR1 agonists for the treatment of neuropsychiatric disorders: One step away 13
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling 12
Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays 11
Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo 5
The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents 4
Further quinolizidine derivatives as antiarrhythmic agents-3 3
High-Throughput Phenotypic Screening and Machine Learning Methods Enabled the Selection of Broad-Spectrum Low-Toxicity Antitrypanosomatidic Agents 3
Anti-α-glucosidase and antiglycation activities of α-mangostin and new xanthenone derivatives: Enzymatic kinetics and mechanistic insights through in vitro studies 1
Totale 5.382
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.847
article - articoli 16.608
book - libri 0
conference - conferenze 881
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 358
Totale 35.694
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.432 63 41 59 121 134 163 207 115 128 220 144 37
2020/2021571 38 26 56 32 33 53 28 51 52 85 77 40
2021/2022824 49 33 94 70 22 45 47 175 59 59 57 114
2022/2023804 67 45 22 78 144 146 3 65 121 5 92 16
2023/2024548 24 67 38 73 37 112 33 32 18 7 49 58
2024/202520 20 0 0 0 0 0 0 0 0 0 0 0
Totale 5.382